Biotech Specialty Pharma

Edge Therapeutics, Inc.

211 Warren Street
Newark, NJ 07103 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Edge seeks to revolutionize treatment to prevent secondary brain injury after hemorrhagic stroke and traumatic brain injury and challenge current oral and intravenous methods by delivering life-saving medicine directly to the brain.

Management Brian A. Leuthner-President & CEO; R. Loch Macdonald, MD, PhD. - Chief Scientific Officer, Carl J. Soranno, Esq. - Executive Vice President, Business Development

Click here for Financial Data
Keywords: subarachnoid hemorrhage, SAH, ruptured aneurysm, SAH, vasospasm Brain research, Pharmaceutical studies, Strokes

Comment


Updated: Oct. 17, 2014


Description

Edge Therapeutics seeks to revolutionize treatment to prevent secondary brain damage after hemorrhagic stroke or traumatic brain injury (TBI) by taking today's minimally effective off-patent drugs and......view more

Products / Services

NimoGel, Edge's lead product, is being developed to prevent secondary strokes after subarachnoid hemorrhage (SAH), which is caused by bleeding into the fluid around the brain. NimoGel combines a gener......view more

Technology / Differentiation

Today's treatment to prevent secondary brain injury after stroke and TBI are limited and only marginally effective because standard oral or intravenous administration fails to provide adequate doses o...view more

Market / Customers

The annual U.S. direct and indirect costs of SAH exceed $20B, and those of TBI total more than $60B. Worldwide, the WHO estimates that sudden brain injury costs hundreds of billions of dollars annual......view more


Competitors / Substitutes / Alternatives

Today's treatment to prevent secondary brain injury after stroke and TBI are limited and only marginally effective because standard oral or intravenous administration fails to provide adequate doses o...view more

Strategy

Edge plans to advance its products to Proof of Concept in 4q2012 / 1Q 2013 and exit via sale of the company....view more

Revenue / Funding

Edge has raised more than $1.2M through a small group of private investors and grants. Edge was awarded a $500,000 grant from the New Jersey Commission on Science and Technology Edison Innovation Fund...view more

Status

MILESTONES TO DATE: In the 15 months since it's founding, Edge Therapeutics has: 1. Submitted U.S. and Worldwide patent applications to protect key intellectual property 2. Secured sourcing for...view more

RELATED COMPANIES